Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

EVP, Chief Commercial Officer

EVP & Chief Financial Officer

CEO, President

EVP, GC, CCO & Corp Sec

EVP & CMO

EVP &Chief Financial Officer

EVP Corp. Affairs, G.C., Sect.

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase II/III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition, the company's other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further, it has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives o...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-02-05	Premium	sold	Premium	Premium	Premium	EVP, Chief Commercial Officer
2024-02-05	Premium	sold	Premium	Premium	Premium	EVP & Chief Financial Officer
2024-02-05	Premium	sold	Premium	Premium	Premium	CEO, President
2024-02-02	Premium	sold	Premium	Premium	Premium	EVP, Chief Commercial Officer
2024-02-02	Premium	sold	Premium	Premium	Premium	EVP & Chief Financial Officer
2024-02-02	Premium	sold	Premium	Premium	Premium	CEO, President
2024-01-23	Premium	acquired	Premium	Premium	Premium	EVP, Chief Commercial Officer
2024-01-23	Premium	acquired	Premium	Premium	Premium	EVP, GC, CCO & Corp Sec
2024-01-23	Premium	acquired	Premium	Premium	Premium	EVP & Chief Financial Officer
2024-01-23	Premium	acquired	Premium	Premium	Premium	CEO, President
2023-05-26	Premium	acquired	Premium	Premium	Premium	-
2023-05-26	Premium	acquired	Premium	Premium	Premium	-
2023-05-26	Premium	acquired	Premium	Premium	Premium	-
2023-05-26	Premium	acquired	Premium	Premium	Premium	-
2023-05-26	Premium	acquired	Premium	Premium	Premium	-
2023-05-26	Premium	acquired	Premium	Premium	Premium	-
2023-05-26	Premium	acquired	Premium	Premium	Premium	-
2023-02-06	Premium	sold	Premium	Premium	Premium	CEO, President
2023-02-02	Premium	sold	Premium	Premium	Premium	EVP, Chief Commercial Officer
2023-02-02	Premium	sold	Premium	Premium	Premium	EVP & CMO
2023-02-02	Premium	sold	Premium	Premium	Premium	EVP & Chief Financial Officer
2023-01-26	Premium	acquired	Premium	Premium	Premium	EVP, Chief Commercial Officer
2023-01-26	Premium	acquired	Premium	Premium	Premium	CEO, President
2023-01-26	Premium	acquired	Premium	Premium	Premium	EVP & Chief Financial Officer
2022-06-09	Premium	bought	Premium	Premium	Premium	CEO, President

RIGL - Rigel Pharmaceuticals Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for RIGL